Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)

Published:2013-01 Issue:1 Volume:24 Page:54-59
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Inoue A.,Kobayashi K.,Maemondo M.,Sugawara S.,Oizumi S.,Isobe H.,Gemma A.,Harada M.,Yoshizawa H.,Kinoshita I.,Fujita Y.,Okinaga S.,Hirano H.,Yoshimori K.,Harada T.,Saijo Y.,Hagiwara K.,Morita S.,Nukiwa T.

Funder

Japan Society for Promotion of Science and Japanese Foundation

Multidisciplinary Treatment of Cancer

Tokyo Cooperative Oncology Group

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/1/54/13788762/mds214.pdf

Reference18 articles.

1. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

2. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

3. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations;Inoue;J Clin Oncol,2006

4. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations;Asahina;Br J Cancer,2006

5. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp;Sutani;Br J Cancer,2006

Cited by 455 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy Improves the Survival of Stage 4 Non–Small Cell Lung Cancer Patients at the US Population Level: The Real‐World Evidence;The Clinical Respiratory Journal;2024-09

2. Revisão Sistemática de Estudos Observacionais sobre o uso de Erlotinibe e Gefitinibe no Tratamento do Câncer de Pulmão de Células Não Pequenas;Revista Brasileira de Cancerologia;2024-08-30

3. Prospects for Perioperative Chemotherapy of Non-small Cell Lung Cancer;Haigan;2024-08-20

4. Strong PD-L1 affect clinical outcomes in advanced NSCLC treated with third-generation EGFR-TKIs;Future Oncology;2024-08-19

5. It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC;Exploration of Targeted Anti-tumor Therapy;2024-07-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3